WBDE(SZ:002082) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-07-15 02:40Group 1 - The company expects a decline in net profit for the first half of 2025 compared to the same period last year [1][2] - The decline in performance is primarily due to the failure of the injection product to pass the centralized procurement and the expansion of other centralized procurement products, along with increased investment in innovative drug research and development [2] Group 2 - The company’s wholly-owned subsidiary has recently obtained an invention patent certificate for a new drug formulation combining ginseng, ginkgo leaves, and millepertuis, which enhances the synergistic effects of these components [5][6] - This patent is expected to protect the intellectual property of new drug research and development, promote the company's innovation capabilities, and enhance its core competitiveness, although it will not have a significant impact on the company's recent production and operations [6]